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Abstract
Objective
The aim of this study was to assess the efficacy (response rate centered on 80%) of a
somatostatin analog with high affinity for 4 somatostatin receptors in reducing the postoper-
ative incidence of symptomatic lymphocele formation following total mastectomy with axil-
lary lymph node dissection.
Setting
This prospective, double-blind, randomised, placebo-controlled, phase 2 trial was con-
ducted in two secondary care centres.
Participants
All female patients for whommastectomy and axillary lymph node dissection were indicated
were eligible for the study, including patients who had received neo-adjuvant chemother-
apy. Main exclusion criteria were related to diabetes, cardiac insufficiency, disorder of car-
diac conduction or hepatic failure.
Interventions
Patients were randomised to receive one injection of either prolonged-release pasireotide
60 mg or placebo (physiological serum), which were administered intramuscularly 7 to 10
days before the scheduled surgery. The study was conducted in a double-blind manner.
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Primary and Secondary Outcome Measures
The primary outcome measure was the percentage of patients who did not develop post-
operative axillary symptomatic lymphoceles during the 2 postoperative months. Secondary
endpoints were the total quantity of lymph drained, duration and daily volume of drainage
and aspirated volumes of lymph.
Results
Ninety-one patients were randomised. Ninety patients were evaluable: 42 patients received
pasireotide, and 48 patients received placebo. The mean estimated response rate were
62.4% (95% Credibility Interval [CrI]: 48.6%-75.3%) in the treatment group and 50.2% (95%
CrI: 37.6%-62.8%) in the placebo group. Overall safety was comparable across groups,
and one serious adverse event occurred. In the treatment group, one patient with known
insulin-depe*ndent diabetes required hospitalization for hyperglycaemia.
Conclusions
With this phase 2 preliminary study, even if our results indicate a trend towards a reduction
in symptomatic lymphocele, pre-operative injection of pasireotide failed to achieve a
response rate centered on 80%. Pharmacokinetics analysis suggests that effect of pasireo-
tide could be optimised.
Trial Registration
ClinicalTrials.gov NCT01356862
Introduction
The principal morbidity following axillary lymph node dissection (ALND) for breast cancer is
the postoperative development of lymphoceles following the removal of an axillary drain. This
condition may result in pain, repeated lymphocele aspiration and infections and could delay
local healing and adjuvant treatments. According to the literature, the incidence of lymphocele
development can vary from 4 to 89% depending on the type of surgery, whether a drain is
inserted or a compression dressing is applied and the time at which the drain is removed [1].
Many interventions have been used to decrease lymphocele formation after ALND, including
the following: suction drains, compressive dressings, shoulder immobilization, fibrin glue, care-
ful hemostasis and lymphostasis and axillary padding [2–8]. Despite all of these measures, lym-
phocele formation remains a frequent postoperative complication after ALND.
Octreotide, a somatostatin analog, has been successfully used for the medical management
of postoperative gastrointestinal and pancreatic fistulae [9]. Two recent studies have demon-
strated its value in reducing lymphoceles following ALNDs performed as part of breast cancer
surgery [10, 11]. However, one recent study, published during our study, did not identify any
significant reduction of lymphorrhea using lanreotide, another somatostatin analogue [12].
Pasireotide, a somatostatin analog registered for Cushing disease [13], that has a high affin-
ity for somatostatin receptors (sst) (30 to 40 times greater for sst1 and sst5 receptors than
octreotide, 5 times greater for sst3 and a slightly lower affinity than octreotide for sst2) is a
promising molecule for this indication [14].
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policies on sharing data and materials.
Based on the encouraging results published with octreotide and the greater effects antici-
pated with pasireotide, we sought to assess the benefits of a one time preoperative administra-
tion of pasireotide in reducing the incidence of axillary lymphocele formation following
mastectomy-axillary node dissection.
The purpose of this trial was to assess whether pre-operative injection of pasireotide long-
acting release (LAR) could reduce the incidence of symptomatic lymphocele formation follow-
ing ALND.
Methods
This prospective, double-blind, randomized, placebo-controlled, phase 2 trial was conducted
in two French centers (Hopital Tenon, Paris and Gustave Roussy, Villejuif) from September
2010 to June 2012 (S1–S3 Files). This study was approved by the national ethics committee and
French health authorities in April 2010 (CPP Ile de France IV) and registered in the EU Clini-
cal Trials Register in May 2010 (N° EudraCT: 2010-018795-24) and in the ClinicalTrials.gov
registry in 2011 (NCT01356862). Because of a change of the principal investigator there was a
delay in registering this study (after enrolment of participants started) in ClinicalTrials.gov reg-
istry. The authors confirm that all ongoing and related trials for this intervention are registered.
Written informed consent was obtained preoperatively in accordance with the ethical stan-
dards of the Helsinki declaration. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript. Protocol is available upon
request to the corresponding author.
Patients and treatment
All female patients for whom mastectomy and ALND were indicated were eligible for the
study, including patients who had received neo-adjuvant chemotherapy. Main exclusion crite-
ria were related to diabetes, cardiac insufficiency, disorder of cardiac conduction or hepatic fail-
ure. Others exclusion criteria are listed in Appendix 1. Patients were randomized to receive one
injection of either prolonged-release pasireotide 60 mg or placebo (physiological serum),
which were administered intramuscularly 7 to 10 days before the scheduled surgery. Randomi-
zations were stratified on whether a neo-adjuvant treatment had been administered prior to
surgery, overweight/obesity with a BMI>25 and the study center. This choice of these variables
was decided because they could influence the rate of post-operative lymphocele and so created
bias. Randomization was carried out by the Statistics Team at Hôpital Saint Louis in charge of
the project (only one randomization list for both centers). The doctor who has included the
patient contacted the randomization center which put in touch (telecopy) with the nurse who
practiced the injection.
The study was conducted in a double-blind manner, i.e., neither the patients nor the treating
surgeon were informed of the type of treatment administered.
Only the consultation nurse was informed of the treatment administered because pasireo-
tide had to be suspended bedside just before injection. This nurse who was in charge of the sus-
pension and the injection was never in contact with the surgeons because she was from another
department and was never present during the patient's hospital stay or subsequent visits war-
ranting aspiration, and the consultations were not held in the same location in either of the two
study centers.
Surgery and post-operative course
All patients underwent mastectomy with ALND. In each center, three surgeons were involved
in this study. Hemostasis and lymphostasis were performed with clips and electrocautery. At
Pasireotide for Lymphocele Prevention after Axillary Node Dissection
PLOS ONE | DOI:10.1371/journal.pone.0156096 June 9, 2016 3 / 13
the end of the surgery, two closed suction drains were left in the operative sites, always at the
same place (the mastectomy site and the ALND site). Daily drainage volume was recorded dur-
ing hospital stay or by a nurse at home if the patient had leave hospital with drains. The drains
were removed when the daily drainage volume was less than 50 cc, and the maximum total
drainage duration was 7 days. Both drains could be removed at the same time. The drain was
with suction for the first four days and without suction starting on the 5th postoperative day.
Endpoints
The primary endpoint of this study was the occurrence of post-operative symptomatic lympho-
cele, which was defined as the absence of aspiration or a unique or iterative aspiration global
volume of lymphocele 60 cc in the 28 days after the intervention or a systematic aspiration
volume 120 cc on the 28th day.
Secondary endpoints were the total quantity of lymph drained up to the time of drain
removal, duration of drainage, daily drainage volume, aspirated volumes of lymph, local heal-
ing, infections, fever, length of hospital stay and length of time to onset of adjuvant
chemotherapy.
Follow-up
The screening was performed during the pre-surgical visit. At the baseline visit (V1) 7 to 10
days prior to surgery, patients signed the informed consent, and pasireotide or the placebo
were injected. In addition, a blood sample for pharmacokinetic monitoring was taken. On the
day of surgery or the day after surgery (V2), data concerning the operation (type of surgery,
duration, intraoperative complications, type and number of drains) and recording of adverse
events were performed. On the day of discharge (V3), the summary of the daily collection of
postoperative data was completed (daily and total drainage volumes, dates on which drains
were removed and overall duration of drainage, postoperative complications, whether aspira-
tion of a symptomatic lymphocele was required, length of hospital stay and recording of
adverse events).
An immediate postoperative visit was required 14 ± 2 days following the surgery (V4) to
record the number of repeated lymphocele aspirations and the volume (patients requiring an
aspiration were seen during the interval between two consultations at the hospital, and data
were collected in the medical file) and adverse events. A second blood sample for pharmacoki-
netic monitoring was taken during this visit.
The postoperative visit was 28 ± 4 days following surgery (V5), and a routine lymphocele
aspiration was warranted and considered positive if the aspirated volume exceeded 120 cc.
Again, data on the number of repeated lymphocele aspirations and the volume were collected,
and adverse events were recorded.
Follow-up visits at 2 months (V6) allowed the recording of late adverse events.
The design of this study is reported in Fig 1.
Statistical methods
Bayesian sequential analysis. The aim of this phase 2, randomized, non-comparative trial
was to assess the rate of patients who did not develop post-operative axillary symptomatic lym-
phoceles after receiving pasireotide or placebo (S4 File). The primary motivation for this
sequential Bayesian strategy were: (1) the uncertainty about the effect of the procedure, (2) the
small sample and (3) it allows continuous monitoring of outcomes throughout the trial. More-
over, as pointed out by Mandrakar and Sargent [15] single-arm phase II trial designs for evalu-
ating an experimental procedure are limited by outcome-trial effect confounding arising from
Pasireotide for Lymphocele Prevention after Axillary Node Dissection
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the inability to separate trial effects (selection biais, etc) from treatment effect on clinical out-
comes. This is the reason why we decided to evaluate this procedure in a phase 2 randomized
non comparative trial. The Bayesian paradigm provided a formal basis for learning about the
response rate (defined as the patients who did not develop post-operative axillary symptomatic
lymphoceles after receiving pasireotide or placebo) in each group as patient outcomes were
observed and thus for making decisions on that basis [16, 17]. We used our experience with post-
operative axillary symptomatic lymphoceles before the beginning of the trial, which was formal-
ized as a prior distribution of the success rate centered on 80% in the treatment group and 60%
in the placebo group. As the patient outcomes in the trial were recorded, the subsequent distribu-
tion of the outcome rate in each group was computed by applying Bayes’ theorem, which yielded
a mean estimated success rate with a 95% credibility interval (CrI; measure of Bayesian precision,
for additional details for the method part please see additional material). Additionally, based on
the subsequent distribution experimental group, early stopping criteria were calculated to allow
early termination of the trial for inefficacy if there was substantial evidence that the estimated
response rate was unacceptably low compared to the expected minimal response rate of 60%.
Results are expressed as medians and first and third quartiles [Q1-Q3] for quantitative data and
counts and percentages for categorical data. Because of the design of the study (phase 2 with con-
trol group), the groups (placebo and treatment) were not compared.
Analyses were performed using R statistical package (online at http://www.R-project.org).
Results
Patients and surgical characteristics
Ninety-one patients were randomized over 18 months. The numbers of included patients were
equal in the two centers (46 patients in Hopital Tenon and 44 patients in Gustave Roussy). Of
these, 43 were randomized to the treatment group and 48 to the placebo group (Fig 2). One
patient randomized to the pasireotide group was injected but not operated on because of an
anaphylactic reaction to anesthesia, which delayed the surgery. The surgery was performed 3
weeks after the injection after anaphylactic tests were completed. Therefore, she was excluded
from the analysis. For the analysis, 42 patients received pasireotide, and 48 patients received
placebo (S5 File). At baseline, the patients’ characteristics were homogeneous in the two groups
(Table 1).
Fig 1. Trial design.
doi:10.1371/journal.pone.0156096.g001
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Fig 2. Flow chart of the trial.
doi:10.1371/journal.pone.0156096.g002
Table 1. Patient and surgical characteristics.
N,%, Median, IQR Pasireotide (n = 42) Placebo (n = 48)
Age (years) 54.5 [45,66.5] 51.5 [43,63]
BMI (kg/m2) 26.7 [23.9,29.3] 24.6 [21.8,29.4]
Obesity deﬁned by a BMI > 25 * 26 (62%) 20 (4%)
Diabetes (n,%) 3 (7%) 2 (4%)
Hypertension (n,%) 13 (31%) 10 (21%)
Post-menopausal (n,%) 27 (64%) 27 (56%)
Neo-adjuvant chemotherapy (n,%) * 15 (36%) 16 (33%)
Tumor size (mm) 25 [15,40] 25 [15,35]
Duration of surgery (min) 125 [91,155] 128 [93.75,155]
Tumor type
Invasive ductal 35 (83%) 41 (85%)
Invasive lobular 6 (14%) 7 (15%)
Other 1 (2%) 0 (0%)
Compression bandage (n,%) 42 (100%) 47 (98%)
Number of patients with metastasis to lymph nodes (n,%) 24 (57%) 23 (48%)
Number of metastatic lymph nodes (n) 1 [0;2] 1 [0;2]
Number of lymph nodes removed (n) 11 [8,14.75] 15 [10,19]
Time between injection and surgery (days) 7 [7,8] 7 [7,8]
Inclusion center (n,%) *
Hopital Tenon 21 (50%) 52%)
Institut Gustave Roussy 21 (50%) 23 (48%)
BMI: Body Mass Index, IQR: Interquartile Range
*: variables used for a stratiﬁcation
doi:10.1371/journal.pone.0156096.t001
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Control group
The median tumor size was 25 mm, and the median surgical duration was 128 min. Fifteen
patients had received neo-adjuvant chemotherapy prior to surgery, and 20 patients (42%) were
considered obese (BMI>25), 62. All had compressive bandages at the end of the surgical
course. The median time between treatment injection and surgery was 7 days. No patients were
lost during the follow-up period. The estimated mean posterior success rate was 50.2% in the
placebo group (95% CrI: 37.6%-62.8%) (Table 2, for additional computational details for
Bayesian analysis please see additional material). The median duration of mastectomy and axil-
lary drainages were 2 days and 3 days, respectively (Table 3 and Fig 3). Twenty-one patients
required repeated lymphocele aspirations, with mean numbers of aspirations of 1.2. Fifteen
patients underwent systematic lymphocele aspiration on day 28 (median volume: 210 ml).
There were 5 wound-healing complications in the placebo group (4 cutaneous necroses and 1
abscess). The median delays between surgery and adjuvant chemotherapy was 49 days.
Pasireotide group
Fifteen patients had received neoadjuvant chemotherapy prior to surgery, and 26 patients
(62%) were considered obese (BMI>25), 62. The median tumor size was 25 mm, and the
median surgical duration was 125 min. Except for one patient, all had compressive bandages at
Table 2. Primary outcome results.
Pasireotide arm Placebo arm
Prior distribution Beta (5.6,1.4) Beta (6.6,4.4)
N 42 48
Number of observed successes 25 23
Estimated mean posterior of success rate 62.4% 50.2%
95% Credibility Interval (CrI) 48.6%-75.3% 37.6%-62.8%
doi:10.1371/journal.pone.0156096.t002
Table 3. Post-operative courses.
Pasireotide (n = 42) Placebo (n = 48)
Median[IQR] or n,%
Duration of drainage (days)
Mastectomy drain 2.5 [1.75,4] 2 [1,4]
Axillary drain 3 [2,5] 3 [2,4]
Total ﬂow (ml)
Mastectomy drain 132.5 [55.5,226] 93 [30,221]
Axillary drain 165 [81,400.2] 162.5 [60,339.2]
Repeated lymphocele aspirations
Number of patients (n, %) 17 (40%) 21 (44%)
Total volume (ml) 270 [135,415] 200 [162.5,260]
Incidence of postoperative febrile episodes (n, %) 1 (2%) 0 (0%)
Incidence of wound healing complications
Hematoma requiring iterative surgery (n, %) 0 (0%) 0 (0%)
Cutaneous necrosis (n, %) 2 (5%) 4 (8%)
Cutaneous abscess (n, %) 1 (2%) 1 (2%)
Length of the hospital stay (days) 5 [4,6] 6 [4,6]
Length of time to onset of adjuvant chemotherapy (days) 54 [37.5,60] 49 [40,58.5]
doi:10.1371/journal.pone.0156096.t003
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the end of the surgical course. The median time between treatment injection and surgery was 7
days. No patients were lost during the follow-up period.
Primary endpoint. The estimated mean posterior success rate (i.e., patients who did not
experience a symptomatic lymphocele) was 62.4% in the Pasireotide group (95% CrI: 48.6%-
75.3%) (Table 2, for additional computational details for Bayesian analysis please see additional
material). The cessation criterion associated with inefficacy was not met; the probability that
the response rate was lower than 60% in the treatment group after 42 inclusions was estimated
at 0.354.
Secondary endpoints (Table 3 and Fig 3). The median duration of mastectomy and axil-
lary drainages were 2.5 days and 3 days, respectively. Seventeen patients required repeated lym-
phocele aspirations with mean numbers of aspirations of 1.4. Twelve patients in the treatment
group underwent systematic lymphocele aspiration on day 28, with a median volume of 200
ml. The median delay between surgery and adjuvant chemotherapy was 54 days. There were 3
wound-healing complications.
Safety. There were no complications related to the injection of the treatment, and all
patients had normal skin appearance at the site of the injection.
One patient had a chest skin infection related to an infected lymphocele, which required
surgical excision. One serious adverse event occurred in a patient with pre-existing insulin-
dependent diabetes, who required hospitalization for hyperglycemia. Pre-inclusion glycated
hemoglobin was acceptable (8%). This patient also experienced a recurrent lymphocele, which
necessitated repeated aspiration. During the hospitalization for hyperglycemia, the patient
developed an infected seroma that required surgery.
Regarding non-serious adverse events, 3 patients in the pasireotide group had diarrhea, and
3 patients in the placebo group complained of constipation. All of the other non-serious
adverse events could be related to the surgery (pain at the surgical site, impaired mobilization
of arms, skin inflammation, bruising and other factors).
Pharmacokinetic results. We compared the pasireotide concentrations in blood samples
taken 14 ± 2 days following surgery (V4) for pharmacokinetic monitoring between patients
with and without symptomatic lymphoceles (Fig 4). No significant difference in the median
pasireotide concentration was noted between the two groups (10.2 ng/ml vs. 11.65 ng/ml for
failure or success, respectively).
Discussion
Our phase 2, double-blind, randomized, placebo-controlled trial did not indicate a decrease in
post-operative symptomatic lymphocele development with the pre-operative injection of pasir-
eotide LAR.
Fig 3. Daily drainage quantities.
doi:10.1371/journal.pone.0156096.g003
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Our data indicate a trend towards a reduction in symptomatic lymphocele formation with
pasireotide. The estimated mean posterior response rate were 62.4% (95% CI: 48.6%-75.3%) in
the treatment group and 50.2% (95% CI: 37.6%-62.8%) in the placebo group. Most of the risk
factors for seroma formation, including body weight, age, number of lymph nodes removed,
overweight and neo-adjuvant chemotherapy were controlled through randomization and strat-
ification. The rate of symptomatic lymphocele formation in this trial was approximately 47%,
which was similar to our preliminary study (40%). Although we failed to demonstrate a signifi-
cant difference with our design, we detected a 12.2% decrease in symptomatic lymphocele
development in treated patients. Based on these results, 550 patients would be necessary to
demonstrate a significant difference in a phase 3 randomized study (275 patients who received
placebo and 275 who received treatment, with alpha = 0.05 and beta = 0.2).
Mode of action of pasireotide
Somatostatin is a widely distributed hormone in the nervous and gastropancreatic systems and
is responsible for a variety of pharmacological and physiological effects. It can inhibit gastroin-
testinal endocrine and exocrine secretion and has anti-inflammatory action [18]. The direct
effect of somatostatin on lymphatic flow has only been observed in the gastrointestinal tract.
Somatostatin receptors have been identified in lymphatic tissues, including those tissues not
associated with the intestinal tract. Therefore, the inhibitory action of somatostatin on gastro-
intestinal lymphatic flow may also apply elsewhere in the body, particularly the lymphatic sys-
tem [19]. Somatostatin may decrease lymphatic flow following axillary lymphadenectomy.
Several series have reported the use of octreotide in the treatment of chylous ascites or in
the management of thoracic duct injury [20]. Although its mechanism of action has not been
studied in depth, octreotide likely acts by inhibiting splanchnic blood flow and limiting the
absorption of triglycerides.
Fig 4. Comparison of mean pasireotide concentrations at day 14 in patients with or without post-
operative symptomatic lymphocele formation.
doi:10.1371/journal.pone.0156096.g004
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Pasireotide is an injectable somatostatin analog. Similar to natural somatostatin and known
analogs, its pharmaceutical efficacy depends on its binding to somatostatin receptors. The five
somatostatin receptors (sst 1 to 5) are expressed in various organs under normal physiological
conditions. Somatostatin analogs activate these receptors, which in turn reduce cell activity
and inhibit hormone synthesis [21]. Octreotide and lanreotide, which are currently used, have
strong affinities for the sst2 receptor and moderate affinities, if any, for the other receptor
types. Pasireotide possesses greater affinity than octreotide for certain somatostatin receptors,
specifically 30 times greater for sst1, 5 times greater for sst3 and 40 times greater for sst5. It
possesses slightly lower affinity for sst2 and none (like octreotide) for sst4 [14].
The side effects described with pasireotide include potential transient, post-prandial, dose-
dependent hyperglycemia, which mainly occurs after administration of a 600-μg dose. Intesti-
nal adverse events have also been reported (diarrhea, nausea and vomiting) but do not gener-
ally warrant medication because they resolve spontaneously as treatment continues.
Somatosatin analogues in lymphocele prevention
In addition to the many articles in the literature detailing the beneficial effects of octreotide on
gastrointestinal and pancreatic fistulae and on regression of chylous ascites and chylothorax, a
few articles have attempted to highlight the effect of octreotide on postoperative lymphoceles.
Two articles have highlighted the positive effects of somatostatin analogs on reducing drain-
age volumes and the incidence of lymphoceles following axillary node dissection in breast can-
cer. In 2003, Carcoforo et al. [10] reported a significant difference between a group of patients
treated with subcutaneous octreotide during the immediate postoperative period and an
untreated group. The treated group had smaller daily drainage volumes (65.4 vs. 94.6 ml,
p = 0.0001), and their drains were removed earlier after surgery (7.1 vs. 16.7 days, p = 0.0001).
Another more recent article by Mahmoud et al. [11] showed the same beneficial effects on the
mean daily drainage volume (104 vs. 145 ml, p = 0.0001), the total duration of drainage (12.7
vs. 25 days, p = 0.0001) and the need for postoperative aspiration of lymphoceles (40 vs. 90%,
p = 0.0001).
More recently, Gauthier et al. [12] have reported the results of a phase 3, double-blind, ran-
domized study using Lanreotide Autogel 90 mg LAR to reduce lymphorrhea volumes in the
axillary drain during the first 4 postoperative days. They showed a non-significant tendency
towards a reduction of the lymphorrhea volume in the lanreotide group (median 292 ml, range
1–965 ml) compared to the placebo group (median 337 ml, range 0–1230 ml). In the group of
patients who only underwent an axillary dissection, the lymphorrhea volume was significantly
reduced in the lanreotide group (p = 0.035) compared to the placebo group. The absence of sig-
nificant differences across the entire population could be explained by a lack of power and the
fact that the authors included women with breast cancer who had to undergo ALND either
alone or with either lumpectomy or mastectomy. To avoid the effects of breast surgery, we
chose to include only patients who underwent mastectomy with ALND.
In 2006, in the renal transplantation field, an article by Capocasale et al. [22] demonstrated
that lymphatic leakage following transplantation was of shorter duration in patients treated
with octreotide. Furthermore, a lower incidence of lymphocele formation was observed after
drain removal.
Differences between the results reported by Carcoforo [10] and Mahmoud [11] and our
results could be partially explained. First, the clinical practices were different. In our practice,
drains were removed before the seventh post-operative day, whereas in the studies by Carco-
foro [10] and Mahmoud11 the mean duration of drainage was between 7 and 25 days. Second,
the other authors both used octreotide 0.1 mg three times a day subcutaneously for 5 [10] or 7
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[11] days, starting on the first postoperative day. In our study, we chose a long-acting release
formulation of pasireotide (pasireotide LAR) with a single injection 7 to 10 days before surgery.
This option was motivated by pharmacokinetic studies that showed that the effect was obtained
from the seventh day after pasireotide LAR injection and remained for up to 30 days [21]. This
study demonstrated that there were two peaks after injection of pasireotide LAR (40 and 60
mg). The first peak was observed on day 1 after administration, which was followed by a
decrease in concentration from days 1 to 7 and a second slow-release peak with maximum con-
centrations at approximately day 20, after which pasireotide plasma concentrations gradually
decreased. A pharmacokinetic analysis in neuroendocrine tumors demonstrated that the resid-
ual concentration at day 28 was 16.5 ng/mL, which is over the concentration observed at day
14 in our study. We cannot exclude that a better timing of injection would have optimize the
effect of pasireotide LAR to prevent lymphocyst [23]. One single injection was easier for the
patients than 15 to 21 subcutaneous injections. Finally, to limit bias due to the type of surgery
performed, we included only mastectomies associated with ALND, unlike Gauthier et al. [12].
Conclusion
Even if our results indicate a trend towards a reduction in symptomatic lymphocele, a one-
time injection of pasireotide LAR is not efficient to prevent symptomatic lymphocele develop-
ment in women undergoing mastectomy with axillary dissection. The optimal timing of pasir-
eotide LAR administration remains controversial based on pharmacokinetics results. Further
clinical studies are warranted.
Appendix 1: Non-Inclusion Criteria
• Patient under the age of 18 years.
• Patient who does not understand French.
• Patient not covered by the French national health insurance system.
• Patient exhibiting one or more contraindications to anesthesia and surgery.
• Patient with a contra-indication to pasireotide.
• Refusal by the patient.
• Scheduled sentinel node procedure.
• Abnormal coagulation or curative anticoagulant treatment.
• Women of child-bearing potential without effective contraception.
• Pregnant or breast-feeding women.
• Poorly controlled diabetes (HbA1c> 8%).
• History of radiotherapy.
• Recurrent breast cancer.
• Patient with a congestive cardiac insufficiency (NYHA category III or IV), an instable angina
pectoris, sustained ventricular tachycardia or ventricular fibrillation episodes or history of
myocardial infarction during the last 6 months.
• Patient presenting an extension of QT interval (QT corrected according to the Fridericia for-
mula (QTcF)) at the screening or baseline (predose)> 450msec.
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• History of syncope or family history of sudden death or significant cardiac arrhythmia.
• Risk factors for torsades de pointes: hypokaliaemia, hypomagnesaemia, known structural or
ischaemic cardiac disease, bradycardia (HR<55/min) or high grade AV block.
• Concomitant disease that could prolong QT or increase exposure to the study medication
including dehydration, renal or hepatic impairment.
• Concomitant medication known to increase the QT interval.
• Patient with an hepatic pathology such as cirrhosis, chronic hepatitis active or persistent, or
an elevation of ALAT rate, ASAT rate twice higher than the normal superior limit (NSL).
• Patient having leucocytes< 3x109/L, Hb< 90% LIN, platelets< 100x109/L.
• Patient having a pathology or medical history susceptible to interfere with the realization of
the study or results evaluation according to the judgment of the investigator or the study
monitor.
• Patient participating to another clinical trial with another molecule in study during the
month before the first dose.
• Known oversensitivity to somatostatine analogs or another component of prolonged release
pasireotide or prolonged release octreotide formulations.
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